Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Trials

Background:

• Chronic bronchitis and COPD patients experience recurrent exacerbations, increasing sputum volume/purulence.
• Exacerbations incur significant personal and healthcare costs, making therapies that reduce their frequency valuable.
• Global prescribing of mucolytics varies, influenced by perceived efficacy.

Purpose of the Study:

• To evaluate the impact of oral mucolytic agents on adults with stable chronic bronchitis or COPD.
• To assess the efficacy of mucolytics in reducing exacerbation frequency and associated disability.

Main Methods:

• Systematic review of randomized controlled trials comparing oral mucolytics with placebo for at least two months.
• Searches conducted across multiple databases, including the Cochrane Airways Group Specialised Register.
• Data extraction by one author, with efforts to obtain missing information from study authors and pharmaceutical companies.

Main Results:

• Twenty-eight trials with 7042 participants showed oral mucolytics significantly reduced exacerbations per patient (21% reduction).
• A significant decrease in disability days was observed with mucolytic treatment.
• Patients receiving mucolytics had a higher likelihood of remaining exacerbation-free and potentially reduced hospitalization rates.

Conclusions:

• Oral mucolytics offer a modest reduction in acute exacerbations and disability days for COPD and chronic bronchitis patients.
• Benefits may be more pronounced in individuals with frequent exacerbations or recurrent hospital admissions.
• Consideration of mucolytics is recommended, particularly during winter, for moderate to severe COPD patients not prescribed inhaled corticosteroids.